Scholarlink

Prostatic obstruction secondary to benign prostatic hypertrophy (BPH) is a common condition in men over 50, characterised by storage and voiding lower urinary tract symptoms (LUTS). First line treatment for symptomatic patients is medical therapy and this chapter discusses the 3 main medication groups utilised: α1-adrenoceptors antagonists (alpha blockers), 5α -reductase inhibitors (5ARIs) and phosphodiesterase 5 Inhibitors (PDE5Is).

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Benign Prostatic Obstruction

  • 章节

  • 发表日期：

    2026年

查看全文
  • Dora Moon

摘要

Prostatic obstruction secondary to benign prostatic hypertrophy (BPH) is a common condition in men over 50, characterised by storage and voiding lower urinary tract symptoms (LUTS). First line treatment for symptomatic patients is medical therapy and this chapter discusses the 3 main medication groups utilised: α1-adrenoceptors antagonists (alpha blockers), 5α -reductase inhibitors (5ARIs) and phosphodiesterase 5 Inhibitors (PDE5Is).